Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nirogacestat - SpringWorks Therapeutics

Drug Profile

Nirogacestat - SpringWorks Therapeutics

Alternative Names: Nirogacestat hydrobromide - SpringWorks Therapeutics; OGSIVEOTM; PF 3084014; PF-03084014; PF-03084014-04

Latest Information Update: 04 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Janssen Biotech; Pfizer; SpringWorks Therapeutics
  • Class Amides; Amines; Antineoplastics; Fluorine compounds; Imidazoles; Naphthalenes; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibroma; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fibroma
  • Phase II Ovarian cancer
  • Phase I/II Multiple myeloma
  • Discontinued Alzheimer's disease; Pancreatic cancer; Precursor T-cell lymphoblastic leukaemia-lymphoma; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 01 Mar 2024 Preregistration for Fibroma in European Union (PO)
  • 28 Feb 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in Belgium (PO, Tablet)
  • 27 Feb 2024 SpringWorks Therapeutics announces intention to submit MAA to the European Medicines Agency for Fibroma, in February 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top